No. She has ruled in favor of patent holders in 90% of completed trials. Additionally, that ruling would have widespread effects in US patent law and discourage drug development (an issue that is already being discussed in regards to antibiotic mfgs).
In Amarin’s case- absolutely not. Amarin is a small company, not a big BP- the judge is well versed in these patent cases, it’s what she specializes in- she knows what game the generics are at- it doesn’t pass the smell test.
Market Data 
Markets 
AI
